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Mechanism of Action of Escherichia coli
Phosphoribosylaminoimidazolesuccinocarboxamide Synthetase
Abstract
The conversion of ATP, l-aspartate, and 5-aminoimidazole-4-carboxyribonucleotide (CAIR) to
5-aminoimidazole-4-(N-succinylcarboxamide) ribonucleotide (SAICAR), ADP, and phosphate by
phosphoribosylaminoimidazolesuccinocarboxamide synthetase (SAICAR synthetase) represents the eighth
step of de novo purine nucleotide biosynthesis. SAICAR synthetase and other enzymes of purine biosynthesis
are targets of natural products that impair cell growth. Prior to this study, no kinetic mechanism was known
for any SAICAR synthetase. Here, a rapid equilibrium random ter-ter kinetic mechanism is established for the
synthetase from Escherichia coli by initial velocity kinetics and patterns of linear inhibition by IMP, adenosine
5‘-(β,γ-imido)triphosphate (AMP-PNP), and maleate. Substrates exhibit mutual binding antagonism, with the
strongest antagonism between CAIR and either ATP or l-aspartate. CAIR binds to the free enzyme up to
200-fold more tightly than to the ternary enzyme−ATP−aspartate complex, but the latter complex may be the
dominant form of SAICAR synthetase in vivo. IMP is a competitive inhibitor with respect to CAIR,
suggesting the possibility of a hydrogen bond interaction between the 4-carboxyl and 5-amino groups of
enzyme-bound CAIR. Of several aspartate analogues tested (hadacidin, l-malate, succinate, fumarate, and
maleate), maleate was by far the best inhibitor, competitive with respect to l-aspartate. Inhibition by IMP and
maleate is consistent with a chemical mechanism for SAICAR synthetase that parallels that of
adenylosuccinate synthetase.
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ABSTRACT: The conversion of ATP, L-aspartate, and 5-aminoimidazole-4-carboxyribonucleotide (CAIR)
to 5-aminoimidazole-4-(N-succinylcarboxamide) ribonucleotide (SAICAR), ADP, and phosphate by
phosphoribosylaminoimidazolesuccinocarboxamide synthetase (SAICAR synthetase) represents the eighth
step of de novo purine nucleotide biosynthesis. SAICAR synthetase and other enzymes of purine
biosynthesis are targets of natural products that impair cell growth. Prior to this study, no kinetic mechanism
was known for any SAICAR synthetase. Here, a rapid equilibrium random ter-ter kinetic mechanism is
established for the synthetase from Escherichia coli by initial velocity kinetics and patterns of linear
inhibition by IMP, adenosine 5′-(â,ç-imido)triphosphate (AMP-PNP), and maleate. Substrates exhibit
mutual binding antagonism, with the strongest antagonism between CAIR and either ATP or L-aspartate.
CAIR binds to the free enzyme up to 200-fold more tightly than to the ternary enzyme-ATP-aspartate
complex, but the latter complex may be the dominant form of SAICAR synthetase in vivo. IMP is a
competitive inhibitor with respect to CAIR, suggesting the possibility of a hydrogen bond interaction
between the 4-carboxyl and 5-amino groups of enzyme-bound CAIR. Of several aspartate analogues tested
(hadacidin, L-malate, succinate, fumarate, and maleate), maleate was by far the best inhibitor, competitive
with respect to L-aspartate. Inhibition by IMP and maleate is consistent with a chemical mechanism for
SAICAR synthetase that parallels that of adenylosuccinate synthetase.
Phosphoribosylaminoimidazolesuccinocarboxamide syn-
thetase [EC 6.3.2.6, 5′-phosphoribosyl-4-carboxy-5-amino-
imidazole:L-aspartate ligase (ADP)] (SAICAR synthetase)1
catalyzes the eighth step in de novo purine nucleotide
biosynthesis:
Lukens and Buchanan (1) first described the enzyme in 1959,
and in 1962, Miller and Buchanan (2) demonstrated its
presence in a variety of life forms and reported the purifica-
tion and properties of the synthetase from chicken liver. More
recently, the Stubbe laboratory purified SAICAR synthetase
from Escherichia coli (3).
Our laboratory has investigated bacterial and mammalian
adenylosuccinate synthetases (AMPSase) since 1958 (4-
7). The substrates for AMPSase and SAICAR synthetase are
identical or similar: GTP, IMP, and ASP for AMPSase
correspond to ATP, CAIR, and ASP for SAICAR synthetase.
In addition, the two reaction products, SAICAR and adenylo-
succinate, are each substrates for adenylosuccinate lyase.
AMPSase and SAICAR synthetase from E. coli, however,
exhibit only 16% sequence identity. SAICAR synthetase
from E. coli is a trimer (3) and from Saccharomyces
cereVisiae a monomer (11), whereas all well-characterized
AMPSases are functional dimers (12-16). Mammalian
SAICAR synthetase is a bifunctional enzyme, combining
5-aminoimidazole ribonucleotide carboxylase (AIR carbox-
ylase) and SAICAR synthetase activities (2), whereas E. coli
and S. cereVisiae SAICAR synthetases have no carboxylase
activity.
L-Alanosine can replace ASP as a substrate in vivo for
SAICAR synthetase and in vitro for AMPSase (8-10). The
product of the SAICAR synthetase reaction, L-alanosyl-5-
amino-4-imidazolecarboxylic acid ribonucleotide, is a potent
inhibitor of AMPSase and adenylosuccinate lyase, being the
compound responsible for L-alanosine toxicity (9). Many
cancers (approximately 30% of all T-cell acute lymphocytic
leukemia, for instance) lack a salvage pathway for adenine
nucleotides and rely entirely on adenylosuccinate synthetase
and de novo biosynthesis (17). L-Alanosine is toxic to cell
lines of such cancers at concentrations well below those that
poison cells with intact salvage pathways. Hence, L-alanosine
may be effective as a chemotherapeutic agent in combination
with other drugs (17). Efforts to further develop specific
inhibitors of de novo purine biosynthesis would benefit from
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1 Abbreviations: SAICAR synthetase, phosphoribosylaminoimid-
azolesuccinocarboxamide synthetase; AMPSase, adenylosuccinate syn-
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ATP + L-aspartate + 5-aminoimidazole-4-
carboxyribonucleotide (CAIR) f 5-aminoimidazole-4-
(N-succinylcarboxamide) ribonucleotide (SAICAR) +
ADP + Pi
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a basic understanding of structure-functions relations in en-
zymes participating in purine biosynthesis, and for SAICAR
synthetase such information is lacking.
We have undertaken studies on E. coli SAICAR synthetase
to determine whether further parallels exist between it and
AMPSase with respect to substrate recognition and possible
reaction mechanisms. Initial velocity kinetics of SAICAR
synthetase, using competitive inhibitors of ATP, CAIR, and
ASP, are consistent with a rapid equilibrium sequential
mechanism, in which substrates add randomly to the active
site, a kinetic mechanism comparable to that of AMPSase
(18, 19). The efficacy of maleate (but not fumarate) as a
competitive inhibitor of SAICAR synthetase with respect to
ASP suggests a cis-like conformation from the amino acid
substrate in its enzyme-bound state, and indeed, ligated
crystal structures of AMPSase indicate a cis-like conforma-
tion for ASP (20). On the other hand, the absence of
inhibition of SAICAR synthetase by hadacidin, and its potent
inhibition of AMPSase, suggests fundamental differences in
the recognition of the R-amino group of ASP by the two
enzymes. IMP is a competitive inhibitor of SAICAR syn-
thetase with respect to CAIR, consistent with the formation
of a purine-like hydrogen-bonded ring between the 4-car-
boxylate and 5-amino groups of CAIR. Finally, mechanisms
of catalysis of AMPSase and SAICAR synthetase may
exhibit significant parallels, such as the use of a single side
chain as a catalytic base in the formation of the carbonyl
phosphate intermediate.
EXPERIMENTAL PROCEDURES
Materials. ATP, adenosine 5′-(â,ç-imido)triphosphate
(AMP-PNP), IMP, ASP, L-malate, maleate, fumarate, NADH,
phosphoenolpyruvate, pyruvate kinase, and lactate dehydro-
genase were purchased from Sigma. 5-Aminoimidazole-4-
carboxamide ribonucleoside (AICARs) was purchased from
Toronto Research Biochemicals. L-Alanosine was obtained
from the Drug Research and Development Branch, National
Cancer Institute, Bethesda, MD. Ampli-Taq DNA poly-
merase was purchased from Midwest Scientific. Restriction
enzymes were purchased from New England Biolabs. E. coli
strains XL1-Blue and BL21(DE3) came from Stratagene and
Invitrogen, respectively. Hadacidin was a gift from Drs.
Bruce Cooper and Fred Rudolph, Department of Biochem-
istry and Cell Biology, Rice University.
PurC Cloning and SAICAR Synthetase Purification. Ge-
nomic DNA was isolated from E. coli strain XL1-Blue using
the Promega genomic DNA purification kit. The open
reading frame encoding SAICAR synthetase was PCR
amplified using the following forward and reverse primers,
respectively: 5′-GCTAGCATATGCAAAAGCAAGCTGAG-
3′ and 5′-CCGCTCGAGTCAGTCCAGCTGTACACC-3′.
The underlined sequences indicate NdeI and XhoI restriction
sites, respectively, which were used to clone the PCR product
into the pet24b vector. The pet24b expression vector,
containing wild-type PurC, was transformed into BL21(DE3)
E. coli, and a single colony was used to inoculate a 100 mL
overnight culture of Luria broth. Six liters of Luria broth in
12 flasks was inoculated with 5 mL of overnight culture each
and grown to an absorbance of 1.0 at 600 nm. The cells
were then cooled to 16 °C, induced with 0.25 mM IPTG,
and allowed to grow an additional 16 h before being
harvested by centrifugation. Purification of native SAICAR
synthetase was performed as described by Meyer et al. (3).
The conventional purification of SAICAR synthetase
requires several steps and, in our hands at least, resulted in
a protein with a tendency toward aggregation. As an
alternative, we incorporated an N-terminal, hexahistidine tag
and employed nickel nitrilotriacetic acid-agarose chroma-
tography. The wild-type PurC gene was subcloned into the
pet100/TOPO vector (Invitrogen) using the forward primer
5′-CACCTCAAATGAAGTTGAACAG-3′ and a reverse
primer identical to that used in the pet24b cloning. Hexa-
histidine-tagged enzyme was expressed as described above
for the native enzyme. The harvested cell pellet was
suspended in 80 mL of 20 mM KPi, 500 mM NaCl, and 10
mM imidazole (pH 8.0) and lysed using a French press at
20000 psi. After centrifugation at 15000g for 45 min, the
cell-free extract was loaded onto a nickel nitrilotriacetic
acid-agarose column and washed with 10 column volumes
of lysis buffer. A second wash was performed with 10
column volumes of lysis buffer containing 40 mM imidazole.
Lysis buffer containing 250 mM imidazole eluted SAICAR
synthetase from the column. Protein purity and concentration
were confirmed by SDS-polyacrylamide gel electrophoresis
(21) and by Bradford assay (22), respectively.
Synthesis of CAIR. 5-Aminoimidazole-4-carboxyribo-
nucleoside (CAIRs) was synthesized from 5-aminoimidazole-
4-carboxamide ribonucleoside (AICARs) under alkaline
conditions as described by Srivastava et al. (23) with minor
modifications as follows: 0.516 g of AICARs was purged
with N2 gas for 10 min prior to addition of 2 mL of freshly
prepared 6 M NaOH. The reaction mixture was refluxed
gently for 4 h under N2 gas and then cooled to 0 °C. Four
milliliters of ethanol was added to the cooled mixture. The
resulting thick syrup was triturated six times with 1 mL of
ethanol and lyophilized overnight. The dry glassy solid from
lyophilization was triturated once with 0.5 mL of methanol
and dried in a Speed-Vac. CAIRs was then resuspended in
500 mL of 5 mM NH4HCO3 and applied to a DEAE-
Sephadex column equilibrated with 5 mM NH4HCO3. The
column was washed with 10 volumes of 20 mM NH4HCO3
before eluting pure CAIRs with 150 mM NH4HCO3. The
product was lyophilized to dryness overnight to remove
volatile salts.
CAIRs was phosphorylated to CAIR using the procedure
described by Meyer et al. (3), which is a modification of
the method of Yoskikawa et al. (24). CAIR was purified
using a DEAE-Sephadex column with a linear gradient of
50-400 mM NH4HCO3. Phosphate content was determined
using alkaline phosphatase to hydrolyze the phosphate from
CAIR. The amount of released inorganic phosphate was
determined by the ammonium molybdate assay (25).
Size-Exclusion HPLC. Determination of the oligomeric
state of hexahistidine-tagged SAICAR synthetase employed
a Tsk-gel Super SW 3000 column from Tosoh Bioscience
and an eluent buffer composed of 50 mM Hepes, pH 7.8,
200 mM KCl, 6 mM MgCl2, and 1 mM dithiothreitol (DTT).
The following standard proteins were injected (total volume
0.1 mL) as a mixture in which each had a concentration of
approximately 2 mg/mL: cytochrome c (12.4 kDa), bovine
serum albumin (66 kDa), aldehyde dehydrogenase (150 kDa),
and â-amylase (200 kDa). SAICAR synthetase (2 mg/mL)
was combined with the standard proteins, injected onto the
Properties of SAICAR Synthetase Biochemistry, Vol. 44, No. 2, 2005 767
column, and run under conditions identical to those of the
standard proteins.
Kinetic Experiments. All enzyme assays were carried out
at 37 °C. Hydrolysis of ATP was monitored at 340 nm using
pyruvate kinase and lactate dehydrogenase to couple the
phosphorylation of ADP by phosphoenolpyruvate to the
oxidation of NADH to NAD+. The buffer conditions used
in the assay were as follows: 50 mM Hepes, 20 mM KCl,
6 mM MgCl2, 0.2 mM NADH, 2 mM phosphoenolpyruvate,
10 units of pyruvate kinase, and 5 units of lactate dehydro-
genase, pH 7.8. Generally, 1 íg of SAICAR synthetase was
used in an assay volume of 1.0 mL. The validity of the
coupled assay was affirmed by a linear relationship, starting
at the origin, in plots of velocity versus enzyme concentra-
tion. Experiments without inhibitor held one of three
substrates at a saturating concentration, while varying the
concentrations of the other two substrates systematically
about their respective Km values. Inhibition experiments held
two of three substrate concentrations at twice their respective
Km values, while varying the concentration of the third
substrate. Concentrations of substrates in specific assays
appear in the figure legends. Kinetic data were fitted using
a MINITAB program with an R value of 2.0 (26, 27). The
most appropriate models of inhibition were selected on the
basis of F-tests and “goodness of fit” analysis.
RESULTS
PurC Cloning and SAICAR Synthetase Purification. Pu-
rification of the native enzyme requires three chromato-
graphic steps and several days. The introduction of the
hexahistidine tag to the N-terminus of SAICAR synthetase
facilitates the purification of large quantities of active
enzyme. Enzyme of at least 95% purity results directly from
nickel nitrilotriacetic acid-agarose chromotography as de-
termined by SDS-polyacrylamide gel electrophoresis (data
not shown).
Synthesis of CAIR. We initially attempted the phospho-
rylation of CAIRs, using bovine liver adenosine kinase (28).
Unfortunately, our preparation of partially purified adenosine
kinase efficiently phosphorylated adenosine and AICARs but
not CAIRs (data not shown). Chemical phosphorylation of
CAIR was complete and selective, giving a purified product
with 1 mole equiv of phosphate (data not shown). The
absorbance spectrum of CAIR was identical to that of Lukens
and Buchanan (29). Purified CAIR supported SAICAR
synthetase activity, and the product of that reaction behaved
identically to SAICAR in anion-exchange and reverse-phase
chromatography. The overall yield of CAIR from AICARs
was approximately 30%.
Size Exclusion HPLC Chromatography. Data from size
exclusion chromatography (not shown) indicate a mass of
approximately 87 kDa for hexahistidine-tagged SAICAR
synthetase. The calculated subunit molecular mass of the
hexahistidine-tagged enzyme (30.827 kDa) suggests a tri-
meric subunit assembly for the native protein. This finding
agrees with data from analytical ultracentrifugation of the
native enzyme (3) and indicates little or no disruption of the
native structure due to the addition of the N-terminal
hexahistidine tag.
Enzymatic Properties. The Km values for CAIR, ASP, and
ATP for native SAICAR synthetase are comparable to the
corresponding values of Table 1 (Ka, Kb, and Kc) for the
hexahistidine-tagged enzyme. The Km for CAIR is more than
5-fold lower than that reported by Meyer et al. (3). The
reason for the difference is unclear; however, CAIR is
unstable even when stored as a dry solid at -20 °C, and
this may account for the descrepancy in Km values. The Km
for CAIR for yeast SAICAR synthetase (1.6 íM) is
comparable to what we find for the E. coli enzyme (10).
The Km for L-alanosine is 0.9 mM.
Metal Ion Specificity of SAICAR Synthetase. Concentra-
tions of Mg2+ (1-10 mM) and Mn2+ (1-10 mM) have no
significant effect on the capacity of the coupling assay to
convert ADP into NAD+. Hence, the coupled assay reflects
the kinetics of SAICAR synthetase over the range of
concentrations of Mg2+ and Mn2+ used here. The maximum
velocity for the Mn2+-activated enzyme is 50% of that for
the Mg2+-activated enzyme. Using saturating substrate levels
(5Km), optimal velocities occurred at 6 and 7 mM Mg2+ and
Mn2+, respectively. As Ca2+ did not support the activity of
the coupling assay, the formation of SAICAR was monitored
directly by absorbance changes at 290 nm. Ca2+ did not
support catalysis in the presence of saturating concentrations
Table 1: Rapid Equilibrium Random Sequential Model for
SAICAR Synthetasea
equilibrium parameter
fitted values and
weighted mean
specific activity 21 ( 1 (Figure 1a)
19 ( 1 (Figure 1b)
17.9 ( 0.8 (Figure 1c)
18.7 ( 0.6 (mean)
EABC ) EBC + A Ka 7.9 ( 0.6 (Figure 1a)
5.9 ( 0.4 (Figure 1b)
6.6 ( 0.3 (mean)
EABC ) EAC + B Kb 63 ( 5 (Figure 1a)
59 ( 4 (Figure 1c)
60 ( 3 (mean)
EABC ) EAB + C Kc 850 ( 80 (Figure 1b)
770 ( 50 (Figure 1c)
790 ( 40 (mean)
EBC ) EC + B Kbc 4 ( 1 (Figure 1a)
EAB ) EB + A Kab 0.5 ( 0.1 (Figure 1b)
EAC ) EA + C Kca 200 ( 30 (Figure 1c)
EAC ) EC + A Kac ) KbcKa/Kb 0.5 ( 0.2
EBC ) EB + C Kcb ) KabKc/Ka 70 ( 20
EAB ) EA + B Kba ) KcaKb/Kc 15 ( 2
EA ) E + A Kia ) Kab/ç 0.04 ( 0.01
Kia)Kac/â 0.05 ( 0.02
0.04 ( 0.01 (mean)
EB ) E + B Kib)Kbc/R 1.0 ( 0.4
Kib)Kba/ç 1.1 ( 0.4
1.0 ( 0.3 (mean)
EC ) E + C Kic)Kca/â 19 ( 6
Kic)Kcb/R 17 ( 6
18 ( 4 (mean)
ç ) Kb/Kbc ) Ka/Kac 15 ( 5
â ) Ka/Kab ) Kc/Kcb 11 ( 3
R ) Kc/Kca ) Kb/Kba 3.9 ( 0.7
a The symbol E represents hexahistidine-tagged SAICAR synthetase,
and substrates A, B, and C represent CAIR, ATP, and ASP, respectively.
Indicated parenthetically are the data used in determining the fitted
value for a parameter. The model has seven independent parameters
(the first entries listed) with all other parameters dependent on the first
seven as indicated. The weighted mean is ∑(1/ój)2Pj/∑(1/ój)2, where
the summations run over independent determinations of a specific
parameter, Pj, and its standard deviation, ój. Values for equilibrium
constants are íM. Parameters R, â, and ç are ratios of equilibrium
constants indicated in the table. All calculations employed six-digit
values, the final entry being rounded to its first significant digit.
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of substrate. Mg2+, Mn2+, and Ca2+ are all activators of
AMPSase. Ca2+-activated AMPSase displayed a maximum
rate of 15% relative to the Mg2+-catalyzed reaction, but the
Km for ASP is severalfold lower in Ca2+-catalyzed than in
Mg2+-catalyzed reactions (30).
A plot of initial velocity against Mg2+ concentration at
fixed levels of ATP, CAIR, and ASP indicates a metal
concentration in excess of that necessary to put all of the
ATP into a MgATP2- complex [formation constant of 73000
M-1 at pH 7.8 (31)]. SAICAR synthetase either requires a
metal ion in addition to that associated with ATP or uses
ATP in a conformation that lowers its affinity for Mg2+
relative to that of the free nucleotide. Similar observations
have been made regarding the Mg2+ concentration for
optimal AMPSase activity (30).
Effect of pH on the SAICAR Synthetase Reaction. SAICAR
synthetase at saturating levels of substrates exhibits optimal
activity at pH 7.8 (data not shown). Over the pH range 7-8,
the coupling system retained its ability to monitor ADP
production from ATP.
Kinetic Mechanism. Initial rate kinetic data were collected,
holding one substrate at a saturating level while varying the
concentrations of the other two substrates systematically
relative to their respective Km values. Double reciprocal plots
of initial velocity for 75 distinct conditions of assay (Figure
1) appear as families of intersecting lines. The convergence
of lines in each of the plots of Figure 1 excludes a number
of mechanisms. Ping-pong mechanisms in which one or two
of the three substrates bind (randomly or ordered) and lead
to a product that dissociates from the enzyme before the
addition of the third substrate will exhibit at least one plot
with a family of parallel lines. Even the steady-state rate
equation for the ordered ter-ter mechanism requires one plot
in Figure 1 to be a family of parallel lines. All of the plots
in Figure 1, however, reveal families of lines that intersect
in the third quadrant, a result consistent with only a sequential
kinetic mechanism. Fits of ping-pong, ordered, or partially
ordered rapid equilibrium models provide decidedly inferior
results and, in some cases, negative values for at least one
parameter. The data of Figure 1, however, are consistent with
the rate equation derived for the rapid equilibrium random
sequential mechanism (Scheme 1):
In the above, Vmax is the maximum velocity, Ka, Kb, Kc, Kbc,
Kab, Kca, and Kic are dissociation constants, defined explicitly
by reference to Scheme 1 and Table 1, and A, B, and C
represent concentrations of CAIR, ATP, and ASP, respec-
tively.
Data for each of the panels in Figure 1 were acquired on
separate days. Hence systematic errors, in particular varia-
tions in Vmax, are a concern in dealing with the analysis of
data from Figure 1. Equation 1, however, requires that all
data be consistent with a single value for Vmax. Limiting forms
of eq 1, which assume one substrate at a saturating
concentration, allow different values for Vmax for each panel
of data in Figure 1:
Goodness of fit values between calculated data (from eqs
2a-c) and observed data (Figure 1) were below 4%.
Equations 2a-c provide two independent determinations of
FIGURE 1: Plots of reciprocal velocity versus reciprocal substrate
concentration. Mg2+ and ATP were added in a ratio of 1:1 to a
solution containing 50 mM Hepes, 20 mM KCl, 6 mM MgCl2, 0.2
mM NADH, 2 mM PEP, 10 units of pyruvate kinase, and 5 units
of lactate dehydrogenase, pH 7.8. Lines come from eqs 2a-c using
the parameters of Table 1. (A) CAIR was varied from 0.75 to 15
íM at fixed ATP concentrations of 15 ([), 30 (9), 60 (2), 120
(b), and 300 (0) íM. The concentration of ASP was 10 mM in
each assay. (B) CAIR was varied from 0.64 to 15 íM at fixed
ASP concentrations of 250 (b), 500 (9), 1000 (2), 2000 (]), and
5000 (0) íM. The concentration of ATP was 500 íM in each assay.
(C) ASP was varied from 250 to 5000 íM at fixed ATP
concentrations of 15 ([), 30 (2), 60 (9), 120 (¢), and 300 (0)
íM. The concentration of CAIR was 20 íM in each assay.
Scheme 1
Vmax/V ) 1 + Ka/A + Kb/B + Kc/C + KaKbc/AB +
KcKab/AC + KbKca/BC + KaKbcKic/ABC (1)
Vmax/V ) 1 + Ka/A + Kb/B + KaKbc/AB (2a)
Vmax/V ) 1 + Ka/A + Kc/C + KcKab/AC (2b)
Vmax/V ) 1 + Kb/B + Kc/C + KbKca/BC (2c)
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the dissociation constants Ka, Kb, and Kc and three inde-
pendent determinations of Vmax. These independent deter-
minations are in reasonable agreement (Table 1). Values for
Vmax (in units of nanomoles of product per minute) are 40 (
3, 37 ( 2, and 35 ( 2 from eqs 2a-c and Figure 1,
respectively. Values for dissociation constants, not explicitly
represented in eqs 2a-c, were determined from relationships
listed in Table 1.
Segel (32) defines a set of interaction parameters, R, â,
and ç, which provide measures of binding antagonism/
synergism between substrates B and C, A and C, and A and
B, respectively. Values for interaction parameters between
0 and 1 reflect binding synergism, whereas numbers greater
than unity indicate binding antagonism. The interaction
parameters R, â, and ç are ratios of equilibrium constants
indicated in Table 1.
FIGURE 2: Plots of reciprocal velocity versus reciprocal substrate concentration at different concentrations of inhibitor. Mg2+ and ATP
were added in a 1:1 ratio. The buffer conditions were 50 mM Hepes, 20 mM KCl, 6 mM MgCl2, 0.2 mM NADH, 2 mM PEP, 10 units of
pyruvate kinase, and 5 units of lactate dehydrogenase, pH 7.8. Lines come from eqs 4a-c using the parameters in Table 2. (A) ATP and
ASP were held constant at 72.6 íM and 2.24 mM, respectively. The inhibitor (IMP) levels were 0 ([), 1 (9), 2 (2), 4 (¢), and 8 (0) mM.
(B) CAIR and ASP were held constant at 16 íM and 2.24 mM, respectively. The inhibitor (IMP) levels were 0 ([), 2.5 (9), 5 (¢), and
10 (0) mM. (C) ATP and CAIR were held constant at 72.6 and 16 íM, respectively. The inhibitor (IMP) concentrations were 0 ([), 2.5
(9), 4.5 (¢), and 9 (0) mM. (D) ATP and ASP were held constant at 72.6 íM and 2.24 mM, respectively. The inhibitor (AMP-PNP)
concentrations were 0 ([), 0.6 (9), 1 (2), and 2 (0) mM. (E) CAIR and ASP were held constant at 16 íM and 2.24 mM, respectively. The
inhibitor (AMP-PNP) concentrations were 0 ([), 0.4 (9), and 0.8 (2) mM. (F) ATP and CAIR were held constant at 72.6 and 16 íM,
respectively. The inhibitor (AMP-PNP) concentrations were 0 ([), 0.6 (9), 1 (¢), and 1.5 (0) mM. (G) ATP and ASP were held constant
at 72.6 íM and 2.24 mM, respectively. The inhibitor (maleate) concentrations were 0 ([), 2 (9), 4 (2), 8 (¢), and 16 (0) mM. (H) CAIR
and ASP were held constant at 16 íM and 2.24 mM, respectively. The inhibitor (maleate) concentrations were 0 ([), 2 (9), 4 (2), 8 (¢),
and 16 (0) mM. (I) ATP and CAIR were held constant at 72.6 and 16 íM, respectively. The inhibitor (maleate) concentrations were 0 ([),
2 (2), 4 (9), 8 (¢), and 16 (0) mM.
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Steady-state ordered and rapid equilibrium random mech-
anisms for two substrate systems are indistinguishable by
data such as those in Figure 1. Rate equations derived by
the assumption of steady-state kinetics for three-substrate
systems are far more complex than for two substrate systems,
and it is not clear in practice whether the data of Figure 1
can exclude all possible steady-state ordered mechanisms for
three substrates. As a means of verifying the rapid equilib-
rium random mechanism for SAICAR synthetase, data were
obtained in the presence of dead-end competitive inhibitors
for ATP, CAIR, and ASP, using protocols developed by
Fromm (33). Finding a set of appropriate competitive
inhibitors, however, proved challenging. AMP-PNP was
satisfactory as a competitive inhibitor with respect to ATP
(Figure 2E). 5-Aminoimidazole ribonucleotide (AIR) exhib-
ited potent inhibition of SAICAR synthetase, but its chemical
instablity resulted in data of unsatisfactory quality. Instead,
inhibition by IMP was reproducible and competitive with
respect to CAIR (Figure 2A). Succinate, fumarate, and malate
did not inhibit SAICAR synthetase at concentrations as high
as 30 mM, and hadacidin caused only 50% inhibition at
concentrations of 30 mM. Inhibition by maleate, however,
was reasonably potent and competitive with respect to ASP
(Figure 2I).
In the analysis of data in Figure 2, if an inhibitor I
competes with A, then the following equilibria hold:
The rate equation (eq 3) for such is
E0 is the total concentration of enzyme, and parameters …0-7,
in Dalziel notation (34), are combinations of equilibrium
constants defined in Scheme 1. The exact definitions of …0-7,
however, have no bearing on our analysis here. Under the
conditions of assay, concentrations of two of three substrates
are fixed at twice their values of Km. By fixing the
concentration of two substrates, for instance, B and C, eq 3
reduces to the mathematical form of linear competitive
inhibition for a single substrate system:
By fixing concentrations of A and B and of A and C, eq 3
simplifies to eq 4b and eq 4c, respectively, both similar in
form to linear noncompetitive inhibition for a single substrate
system:
Hence, of the three plots for a specific inhibitor, one is
competitive, but the other two are noncompetitive. Due to
the symmetery of the random mechanism, inhibitors com-
petitive with respect to B and C will result in analogous
patterns of inhibition, i.e., a competetive inhibitor for B will
exhibit noncompetitive inhibition patterns with respect to
substrates A and C, and a competitive inhibitor for C will
exhibit noncompetitive inhibition patterns with respect to
substrates A and B. The inhibition patterns illustrated in
Table 2 are unique to the rapid equilibrium random ter-ter
mechanism.
The protocol used here does not provide numerical values
for the constants of inhibition K1-9. K′, Ka′, Kb′, Kc′, Kis′,
and Kii′ in eqs 4a-c are related to …0-7, K1-9, and A, B,
and C by relatively complex relationships. In eq 4a, for
instance, Ka′/Kis′ ) …1/K9 + …4/(CK8) + …5/(BK6) + …7/
(BCK1). Hence, the constants reported in Table 2 are apparent
values. Kii′ is the apparent inhibition constant derived from
the change in the intercept with increasing inhibitor con-
centration for a noncompetitive model, and Kis′ is the
apparent inhibition constant derived from the change in slope
with increasing inhibitor concentration of a noncompetitive
or competitive model. The analysis here rigorously estab-
lishes whether the mechanism of inhibition is competitive
or noncompetitive, thereby determining the mechanism of
SAICAR synthetase.
DISCUSSION
An examination of the literature reveals that very little
information is available on the mechanism of action
of SAICAR synthetase. Because of our long interest in
AMPSase, dating from 1958 (4), and the obvious similarity
between the substrate specificities of the two enzymes, we
chose to investigate SAICAR synthetase in detail.
Table 2: Mechanisms of Inhibition for Specific Substrate-Inhibitor
Combinationsa
inhibitor
substrate AMP-PNP IMP maleate
ATP competitive noncompetitive noncompetitive
Kis′ ) 0.26 ( 0.02 Kis′ ) 7 ( 1 Kis′ ) 12 ( 1
Kii′ ) 9 ( 2 Kii′ ) 50 ( 30
CAIR noncompetitive competitive noncompetitive
Kis′ ) 0.6 ( 0.2 Kis′ ) 9.1 ( 0.4 Kis′ ) 15 ( 9
Kii′ ) 4 ( 2 Kii′ ) 40 ( 10
ASP noncompetitive noncompetitive competitive
Kis′ ) 0.7 ( 0.1 Kis′ ) 7 ( 1 Kis′ ) 16 ( 3
Kii′ ) 0.6 ( 0.1 Kii′ ) 13 ( 6
a Details of the conditions of assay are given in the legend to Figure
2. Kis′ is the apparent inhibition constant determined from the slope of
the rate equation, and Kii′ is the apparent inhibition constant determined
from the intercept of the rate equation. Inhibition constants are in units
of mM.
E0/V ) K′ + I/Kii′ + Kc′/C + Kc′/Kis′(I/C) (4b)
E0/V ) K′ + I/Kii′ + Kb′/B + Kb′/Kis′(I/B) (4c)
E + I ) EI, K1
EI + B ) EIB, K2
EIB + C ) EIBC, K3
EI + C ) EIC, K4
EIC + B ) EIBC, K5
EB + I ) EIB, K6
EIB + C ) EIBC, K7
EC + I ) EIC, K8
EBC + I ) EIBC, K9
E0/V ) …0 + (…1/A)(1 + I/K9) + …2/B + …3/C +
(…4/AC)(1 + I/K3) + (…5/AB)(1 + I/K6) + …6/BC +
(…7/ABC)(1 + I/K1) (3)
E0/V ) K′ + Ka′/A + Ka′/Kis′(I/A) (4a)
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The kinetic mechanism of SAICAR synthetase is sequen-
tial with the random addition of substrates. The observed
mechanism is the same as that determined for E. coli
AMPSase by comparable methods (18). Even though the two
enzymes have a common kinetic mechanism, significant
differences are evident. Data from equilibrium isotope
exchange kinetics and electron paramagnetic resonance
indicate strong synergism in the binding of IMP and GTP
in bacterial and mammalian AMPSases (19, 36). The
synergism probably reflects the formation of 6-phosphoryl-
IMP, a reaction that occurs in the active site of AMPSase in
the absence of ASP (36-38). In contrast, the interaction
parameters (R, â, and ç) from the fit of eq 1 are positive,
indicating the presence of substrate binding antagonism for
SAICAR synthetase. The data here offer no evidence for a
tightly bound phosphoryl intermediate but cannot exclude
the formation of such an intermediate.
The Kia value in Table 1 infers a tight interaction between
CAIR and the free enzyme, but under in vivo conditions ATP
and ASP may always saturate the active site as there is lesser
binding antagonism between these substrates (R ) 3.9) than
for ATP and CAIR (ç ) 15) and ASP and CAIR (â ) 11).
Hence, the Michaelis constant Ka, some 100-fold higher than
Kia, may better represent the in vivo binding affinity of CAIR
to SAICAR synthetase. If antagonism between CAIR and
ATP is due to steric interactions involving the ç-phosphoryl
group, then ADP could be a potent feedback inhibitor of
SAICAR synthetase. Maintaining the enzyme as a ternary
EâATPâASP complex in vivo may be the strategy by which
SAICAR synthetase avoids feedback inhibition not only by
ADP but by SAICAR as well.
Succinate, L-malate, and fumarate, Krebs cycle intermedi-
ates, are present in E. coli at total concentrations (ap-
FIGURE 3: Chemical structures of hadacidin and L-alanosine.
FIGURE 4: Parallels between proposed chemical mechanisms of AMPSase and SAICAR synthetase. (A) A putative catalytic base abstracts
a proton from the 5-amino group of CAIR in SAICAR synthetase, enhancing the nucleophilic properties of the oxygen that attacks the
ç-phosphoryl group of ATP (top). The catalytic base, Asp13 in E. coli AMPSase, abstracts the proton from the N-1 position of IMP,
generating the 6-oxyanion that attacks the ç-phosphoryl group of GTP (bottom). Reprotonation of atom N-5 of CAIR (top) and atom N-1
of IMP (bottom) localizes positive charge on C-4 of CAIR and C-6 of IMP, respectively. (B) Nucleophilic attack by the R-amino group of
ASP results in tetrahedral transition states (SAICAR synthetase, top; AMPsase, bottom) and the formation of product bound to the active
site in a high-energy conformation. Products relax into minimum energy conformers in the bulk solution.
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proximately 1 mM) comparable to that of ASP (39).
Evidently, both AMPSase and SAICAR synthetase have
evolved mechanisms which favor the selection of ASP over
other relatively abundant dicarboxylic acids, as neither
succinate, L-malate, nor fumarate inhibit SAICAR synthetase
at concentrations of up to 30 mM, and of the above, only
succinate is a weak inhibitor of AMPSase (Ki  1 mM) (5).
L-Malate, a putative substrate of yeast SAICAR synthetase
(10), is not a substrate for the E. coli enzyme.
By definition, the substrate and inhibitor in competitive
inhibition need only be mutually exclusive in their binding;
however, if the substrate and inhibitor are similar in structure,
it is reasonable to assume that both ligands compete for the
active site. Inhibition of SAICAR synthetase by maleate, a
property shared by AMPSase (5), infers a cis-like conforma-
tion for ASP in its enzyme-bound state. Indeed, the succinyl
moiety of adenylosuccinate adopts such a conformation in
its crystallographic complexes with AMPSase (20). The
requirement for a cis-like conformer presumably allows
AMPSase and SAICAR synthetase to discriminate against
fumarate.
The mechanism by which SAICAR synthetase avoids
inhibition by succinate and malate suggests a critical role
for the R-amino group in the recognition of ASP. The large
value for the interaction parameter â (Table 1), for instance,
infers significant binding antagonism between ASP and
CAIR. The most probable source of that antagonism is a
steric clash between the R-amino group of ASP and the
carbon atom of the 4-carboxyl group of CAIR. Succinate
would avoid that steric clash and, as a consequence, should
bind to the active site with higher affinity than ASP. Yet,
succinate is not an inhibitor of SAICAR synthetase. This
“succinate paradox” can be explained if the recognition of
the R-amino group of ASP is a prerequisite for the binding
of its carboxyl groups. The absence of malate inhibition
further suggests an absolute need for two hydrogen bonds
involving the R-amino group, both of which are proton
donors to the protein.
The lack of inhibition of SAICAR synthetase by hadacidin
(Figure 3) further underscores a fundamental difference
in the recognition of ASP by SAICAR synthetase and
AMPSase. For the latter enzyme, hadacidin is a potent
inhibitor (Ki  10-6 M), competitive with respect to ASP
(40-42). The N-formyl group of hadacidin coordinates the
active site Mg2+ in AMPSase, while its N-hydroxyl group
hydrogen bonds with an essential aspartyl side chain (12,
36-38). The N-formyl and N-hydroxyl groups of hadacidin
together may support a more stable set of interactions than
does the R-carboxyl group of ASP (3). Hadacidin, however,
does not have a functional group analogous to the R-amino
group of ASP and, consistent with the hypothesis above, does
not bind with high affinity to SAICAR synthetase. L-
Alanosine, on the other hand, retains the R-amino group and
supports SAICAR synthetase activity with a Km nearly equal
to that of ASP.
As CAIR competes with IMP for the active site of
SAICAR synthetase, its 4-carboxyl and the 5-amino groups
may form an intramolecular hydrogen bond and mimic the
6-atom ring of a purine nucleotide. Recognition of CAIR as
a pseudopurine nucleotide suggests parallels between the
chemical mechanism of AMPsase, well established by
investigation (7, 12, 15, 36-38), and that of SAICAR
synthetase (Figure 4). Proton abstraction by a catalytic base,
phosphorylation of the resulting oxyanion, reprotonation of
the phosphoryl intermediate to generate a carbocation, and
the nucleophilic addition of ASP represent plausible steps
in the chemical mechanisms of both enzymes.
Regardless of similarities in the kinetic mechanisms of
SAICAR synthetase and adenylosuccinate synthetase estab-
lished here, and the suggested similarities in chemical
mechanism, these two enzymes seem to have evolved
different strategies for the recognition of a common substrate
(ASP) and the extent to which they stabilize their respective
carbonyl phosphate intermediates. Structural investigations
should more precisely define protein-ligand interactions and
provide the basis for experiments to test putative similarities
in the chemical mechanisms of SAICAR synthetase and
AMPSase.
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